Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
作者信息
GeurtsvanKessel Corine H, de Vries Rory D
机构信息
Department of Viroscience, Erasmus Medical Center, 3015 CN Rotterdam, Netherlands.
Department of Viroscience, Erasmus Medical Center, 3015 CN Rotterdam, Netherlands.
出版信息
Lancet Infect Dis. 2022 Dec;22(12):1652-1654. doi: 10.1016/S1473-3099(22)00517-5. Epub 2022 Sep 5.
Abstract
摘要
相似文献
1
Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
Lancet Infect Dis. 2022 Dec;22(12):1652-1654. doi: 10.1016/S1473-3099(22)00517-5. Epub 2022 Sep 5.
2
A Pandemic Success Story: Distribution and Administration of COVID-19 Vaccines.
J Public Health Manag Pract. 2022;28(6):749-750. doi: 10.1097/PHH.0000000000001651.
3
Lessons Relearned? H1N1, COVID-19, and Vaccination Planning.
J Public Health Manag Pract. 2021 Jan/Feb;27 Suppl 1, COVID-19 and Public Health: Looking Back, Moving Forward:S106-S110. doi: 10.1097/PHH.0000000000001289.
4
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2040330. doi: 10.1080/21645515.2022.2040330. Epub 2022 Mar 23.
5
COVID-19 pandemic and attitudes towards influenza and pneumococcal vaccines.
Pediatr Pulmonol. 2022 Jun;57(6):1540. doi: 10.1002/ppul.25885. Epub 2022 Mar 14.
6
The COVID-19 pandemic momentum: can it be used to support improvements in healthcare worker influenza vaccination?
Expert Rev Vaccines. 2021 Aug;20(8):919-920. doi: 10.1080/14760584.2021.1930533. Epub 2021 Jun 7.
7
The Dreaded "Twindemic" of Influenza and COVID-19 Has Not Yet Materialized-Might This Be the Year?
JAMA. 2022 Oct 18;328(15):1488-1489. doi: 10.1001/jama.2022.15062.
8
COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness.
Lancet Glob Health. 2022 Apr;10(4):e570-e573. doi: 10.1016/S2214-109X(22)00075-4.
9
Extinction of the Influenza B Yamagata Line during the COVID Pandemic-Implications for Vaccine Composition.
Viruses. 2022 Aug 9;14(8):1745. doi: 10.3390/v14081745.
10
Attitudes towards influenza and pneumococcal vaccines in parents of asthmatic children during the COVID-19 pandemic.
Pediatr Pulmonol. 2022 Jun;57(6):1541-1542. doi: 10.1002/ppul.25886. Epub 2022 Mar 14.
引用本文的文献
1
Effects of SARS-CoV-2 Vaccines on Sperm Quality: Systematic Review.
JMIR Public Health Surveill. 2023 Dec 6;9:e48511. doi: 10.2196/48511.
2
Taking stock of the mutations in human SARS-CoV-2 spike proteins: From early days to nearly the end of COVID-19 pandemic.
Curr Res Struct Biol. 2023 Oct 5;6:100107. doi: 10.1016/j.crstbi.2023.100107. eCollection 2023.
本文引用的文献
1
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lancet Infect Dis. 2022 Dec;22(12):1716-1727. doi: 10.1016/S1473-3099(22)00502-3. Epub 2022 Sep 5.
2
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
Sci Immunol. 2022 Sep 23;7(75):eabq4450. doi: 10.1126/sciimmunol.abq4450.
3
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
Sci Immunol. 2022 Mar 25;7(69):eabo2202. doi: 10.1126/sciimmunol.abo2202.
4
Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
PLoS One. 2022 Feb 2;17(2):e0263468. doi: 10.1371/journal.pone.0263468. eCollection 2022.
5
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
Nat Med. 2022 Mar;28(3):486-489. doi: 10.1038/s41591-022-01704-7. Epub 2022 Jan 20.
6
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8.
7
Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield®) and BBV-152 (Covaxin®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.
Vaccine. 2021 Oct 22;39(44):6492-6509. doi: 10.1016/j.vaccine.2021.09.055. Epub 2021 Sep 24.
Zotero 插件